Founder and CEO

Dr. Meretzki is a seasoned leader in the Life Science field, having founded several biotech companies, including Pluristem, where he served as CEO and CTO. He holds a Ph.D. in biotechnology from the Technion - Israel Institute of Technology, in collaboration with the Weizmann Institute of Science, Israel. His proven operational, management, and leadership abilities are instrumental in driving Bonus Biogroup's in its mission to revolutionize regenerative medicine.

Chief Financial Officer

Mr. Livne has been instrumental in shaping Bonus Biogroup's financial strategy since 2014. Prior to joining the company, he served as CFO at Bee Contact Communication Ltd., a publicly-traded company (TASE), and as Chief Controller at Dexcel Pharma, a leading international pharmaceutical company. With an MBA in Finance and a BA in Accounting and Economics from The Hebrew University, Mr. Livne brings a wealth of financial expertise to the team.

Chief Operations Officer.

Dr. Ben-David oversees all of Bonus Biogroup's operations, bringing his extensive experience in R&D and operations management to the role. He has been instrumental in the development of all of Bonus Biogroup’s innovative products. With a Ph.D. in medical sciences from the Technion Faculty of Medicine and a specialization in adult stem cells, Dr. Ben David is a key player in the company's mission to advance regenerative medicine.

VP Regulatory & Clinical Affairs

Dr. Kivity brings a wealth of experience in global regulatory and clinical affairs to Bonus Biogroup. With a strong background in pharma, biotech, and medical device companies, she has successfully led submissions to regulatory authorities worldwide. Holding a Ph.D. and MBA degrees from the Technion, the Israeli Institute of Technology, Dr. Kivity ensures that Bonus Biogroup's products meet the highest regulatory standards.

VP Research & Development

Dr. Atara Novak spearheads Bonus Biogroup's R&D operations. With 15 years of experience in Stem Cells and over ten years in cell therapy, she is a leader in her field. Holding a Ph.D. from the Technion Faculty of Medicine, Dr. Novak is at the forefront of translating scientific breakthroughs into advanced biotechnologies. Her leadership ensures the creation of cutting-edge products that transform innovative technologies into life-changing solutions for patients.

VP Quality Assurance

Dr. Corinne Chemouny, our VP of Quality Assurance, brings over 20 years of experience in aseptic manufacturing, GMP, and Quality Affairs. She completed her residency in France and served as Pharmacist-in-Charge at Taro Pharmaceuticals before joining Bonus Biogroup. Her extensive experience ensures the highest standards of quality in our operations.

VP Business Development

Dr. Tomer Bronshtein, our VP of Business Development, has over 15 years of experience in R&D and translating Next Generation Therapies. He is instrumental in identifying and developing opportunities to increase Bonus Biogroup's value for patients, healthcare providers, and strategic partners. Additionally, he is responsible for planning and managing the Company's stakeholder engagement efforts, ensuring strong relationships and effective communication with all our partners.

Executive Chairman of the Board

Mr. Rauch brings a wealth of financial expertise to his role, having served as the Chief Economist and Manager of the Economics Department at Leumi PIA, Israel’s largest mutual fund company at the time. He holds an MBA in Finance & Accounting and Computers & Information Systems from Tel Aviv University and a BA in Economics and Business Administration from Bar-Ilan University.

Director

Mr Gil Shapira is the founder and CEO of Propharma Ltd. Founder and partner in Q-il Ltd. Having 30 years experience in managing and implementing projects in the pharmaceutical and biotech industries. Specializing in designing, construction and validation process. Mr Shapira served for 18 years as a CEO of A.D Cleanroom engineering Ltd

External Director

Mr. Shafir is a Partner-CEO in the strategic consulting company Yanai Group and Yanai Peleg & Co., an investment banking company. Mr. Shafir studied Enocmincs at the Hebrew University, Jerusalem.

Director

Mr. Ariel is the CEO of MILOUOT, a company developing, processing, and marketing agricultural produce. Until 2021, he served as the CEO of Biological Industries, a leading supplier to the life science industry that was recently merged into Sartorius AG. Mr. Ariel holds a B.Sc. degree in mechanical engineering.

Director

Ms. Assays is the General Manager of SISMA (www2.sisma.org.il), a non-profit educational organization, and a former member of the National Petroleum Council, Ministry of Energy, Israel. She holds an MBA degree and a BA degree in economics and criminology.

MD

Prof. Rozen is the Head of the Department of Orthopedic Surgery at Ha’Emek Medical Center, Afula. He is the Founder of the Institute for Bone Repair at Rambam Health Care Campus, Haifa, and the Head of the Department of Orthopedic and Traumatology at Zvulun Medical Center, Haifa. Prof. Rozen is a highly recognized researcher in orthopedics with >90 papers published and a particular interest in non-healing fractures making him highly qualified to lead our orthopedic studies.

 DMD

Dr. Tzur is a senior oral and maxillofacial surgeon specializing in implant surgery and craniomaxillofacial rehabilitation and is the former Director of the Oral & Maxillofacial Surgery Unit at Assaf Harofeh Medical Center. He has over 30 years of experience in all aspects of the reconstruction and rehabilitation of hard and soft tissue defects of the oral cavity, jaws, and facial structures. In addition, he is involved in dent-alveolar and orthogenetic surgery, reconstruction of disease and trauma-induced defects, and dental implantology.

MD

Prof. Ullman is the Head of the Department of Plastic and Reconstructive Surgery and Burn Unit at Rambam Health Care Campus and runs the Aesthetic Plastic Surgery Service at the hospital. The main research interests of Prof. Ullman include burn wound healing, fat graft survival, lasers, and complicated traumas. In addition, Prof. Ullmann is a Senior Clinical Lecturer at the Rappaport Faculty of Medicine at the Technion.

Mr. Hoenlein served until 2022 as the Executive Vice Chairman/CEO of the Conference of Presidents of Major American Jewish Organizations, the coordinating body for 53 national Jewish organizations. He received his B.A. from Temple University and completed his doctoral course work at the University of Pennsylvania, where he taught International Relations and was a Middle East specialist at the Foreign Policy Research Institute. He was the Founding Executive Director of the JCRC of Greater New York and the Greater New York Conference on Soviet Jewry. Mr. Hoenlein appears regularly in the media, has three weekly U.S. national radio broadcasts, and has lectured and met leading officials worldwide. He has received numerous awards from the U.S. and foreign governments and institutions, including four Honorary Doctorates.

Mr. Ben Shoshan is the Managing Partner of the Southern Isreal Bridging Fund (SIBF). He has over 15 years of global experience in managing capital, as well as managing and mentoring startup companies. Mr. Ben Shoshan serves as chairman and member of the board of directors of several start-up companies and organizations, both profit and non-profit. Or was also a partner in Sherpa InnoVentures VC fund and is deeply involved in Israel’s venture capital industry.